Ronald M Goldenberg (Ronald Goldenberg)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 14

Top Topics

Ankylosing Spondylitis

Systematic Review

Top Venues

Diabetes, obesity & metabolism

The New England journal of medicine

Diabetes therapy : research, treatment and education of diabetes and related disorders

This page only lists publications with an associated author ORCID identifier.

Publications

Ronald M Goldenberg
A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'. Diabetes, obesity & metabolism (2024)
Ronald M Goldenberg
A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'. Diabetes, obesity & metabolism 26 (7) (2024)
Ronald M Goldenberg
A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'. Diabetes, obesity & metabolism 26 (7) (2024)
Ronald M Goldenberg, Akshay B Jain
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390. Diabetes care 46 (5) (2023)
Ronald M Goldenberg
A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'. Diabetes, obesity & metabolism (2023)
Ronald M Goldenberg, Jeremy D Gilbert, Priya Manjoo, Sue D Pedersen, Vincent C Woo, Julie A Lovshin
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists. Obesity reviews : an official journal of the International Association for the Study of Obesity (2023)
Ronald M Goldenberg, Vanita R Aroda, Liana K Billings, Anders Meller Donatsky, Marie Frederiksen, David C Klonoff, Balamurali Kalyanam, Richard M Bergenstal
Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study. Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Ronald M Goldenberg, Akshay B Jain
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390. Diabetes care 46 (5) (2023)
Ronald M Goldenberg, Alice Y Y Cheng, Tess Fitzpatrick, Jeremy D Gilbert, Subodh Verma, Julia J Hopyan
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists. Stroke 53 (5) (2022)
Natalia McInnes, Stephanie Hall, Irene Hramiak, Ronald J Sigal, Ronald M Goldenberg, Nikhil Gupta, Remi Rabasa-Lhoret, Manoela Braga, Vincent Woo, Farah Sultan, Rose Otto, Ada Smith, Diana Sherifali, Yan Yun Liu, Ulagamadesan Venkatesan, null null, null null
Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. Diabetes care (2021)
Ronald M Goldenberg, Vanita R Aroda, Liana K Billings, A Sia Louise Christiansen, Anders Meller Donatsky, Ehsan Parvaresh Rizi, Gracjan Podgorski, Katarina Raslova, David C Klonoff, Richard M Bergenstal
Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes, obesity & metabolism 23 (11) (2021)
Julio Rosenstock, Harpreet S Bajaj, Andrej Janez, Robert Silver, Kamilla Begtrup, Melissa Voigt Hansen, Ting Jia, Ronald M Goldenberg, null null
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. The New England journal of medicine 383 (22) (2020)
Ronald M Goldenberg, Jeremy D Gilbert, Irene M Hramiak, Vincent C Woo, Bernard Zinman
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes, obesity & metabolism 21 (10) (2019)
Ronald M Goldenberg, Peter Assimakopoulos, Jeremy D Gilbert, Irving S Gottesman, Jean-François Yale
A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes. Diabetes, obesity & metabolism 20 (9) (2018)